Nothing Special   »   [go: up one dir, main page]

PL1765397T3 - Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR) - Google Patents

Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)

Info

Publication number
PL1765397T3
PL1765397T3 PL05754219T PL05754219T PL1765397T3 PL 1765397 T3 PL1765397 T3 PL 1765397T3 PL 05754219 T PL05754219 T PL 05754219T PL 05754219 T PL05754219 T PL 05754219T PL 1765397 T3 PL1765397 T3 PL 1765397T3
Authority
PL
Poland
Prior art keywords
upar
upa
urokinase
receptor
complex
Prior art date
Application number
PL05754219T
Other languages
English (en)
Inventor
Graham C Parry
Andrew P Mazar
Original Assignee
Tactic Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactic Pharma Llc filed Critical Tactic Pharma Llc
Publication of PL1765397T3 publication Critical patent/PL1765397T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
PL05754219T 2004-05-25 2005-05-25 Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR) PL1765397T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57389604P 2004-05-25 2004-05-25
PCT/US2005/018322 WO2005116077A2 (en) 2004-05-25 2005-05-25 LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY
EP05754219A EP1765397B1 (en) 2004-05-25 2005-05-25 Inhibitory antibodies binding the complex of urokinase-type plasminogen activator (uPA) and its receptor (uPAR)

Publications (1)

Publication Number Publication Date
PL1765397T3 true PL1765397T3 (pl) 2013-04-30

Family

ID=35451457

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05754219T PL1765397T3 (pl) 2004-05-25 2005-05-25 Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)

Country Status (16)

Country Link
US (1) US8101726B2 (pl)
EP (1) EP1765397B1 (pl)
JP (1) JP4890449B2 (pl)
KR (1) KR20070047246A (pl)
CN (1) CN101022830A (pl)
AU (1) AU2005248400A1 (pl)
CA (1) CA2568428C (pl)
DK (1) DK1765397T3 (pl)
ES (1) ES2398221T3 (pl)
IL (1) IL179565A0 (pl)
MX (1) MXPA06013709A (pl)
PL (1) PL1765397T3 (pl)
PT (1) PT1765397E (pl)
RU (1) RU2006145905A (pl)
WO (1) WO2005116077A2 (pl)
ZA (1) ZA200610578B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647380A1 (en) * 2006-03-21 2007-09-27 David T. Weaver Methods for humanizing antibodies and humanized antibodies made thereby
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
PT2117571T (pt) * 2006-12-08 2017-06-14 Monopar Therapeutics Inc Resumo
US8815519B2 (en) 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US9345739B2 (en) * 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
JP5798037B2 (ja) * 2008-11-06 2015-10-21 ユニバーシティ オブ マイアミ 蛋白尿腎疾患の病因における可溶性ｕＰＡＲの役割
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
SG191142A1 (en) 2010-12-22 2013-07-31 Ifom Fond Istituto Firc Di Oncologia Molecolare uPAR-ANTAGONISTS AND USES THEREOF
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
WO2012154218A2 (en) 2011-05-09 2012-11-15 The University Of Miami Reducing soluble urokinase receptor in the circulation
AU2012293720A1 (en) 2011-08-05 2014-02-27 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Constitutively active uPAR variants and their use for the generation and isolation of inhibitory antibodies
AU2014233055B2 (en) * 2013-03-15 2018-08-09 Board Of Regents, The University Of Texas System Inhibition of pulmonary fibrosis with nutlin-3a and peptides
CN105368859B (zh) * 2015-11-25 2019-10-18 王任直 一种嵌合抗原受体hCD87-CAR及载有hCD87-CAR基因结构的慢病毒及质粒及其应用
US10959062B1 (en) 2018-04-19 2021-03-23 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
US10681506B1 (en) 2018-04-19 2020-06-09 Tango Tango, Inc. System and method for push-to-talk over cellular integration with software defined radio
KR20210084453A (ko) 2018-09-10 2021-07-07 렁 세라퓨틱스, 인크. Cav-1 단백질의 변형된 펩타이드 단편 및 섬유증의 치료에 있어서 이의 용도
JP2022513317A (ja) * 2018-09-28 2022-02-07 ヨッヘン ライザー ｓｕＰＡＲならびに急性腎傷害の予測および治療
AU2022276433A1 (en) * 2021-05-21 2023-12-07 Monopar Therapeutics Inc. Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use
CA3221342A1 (en) * 2021-06-11 2022-12-15 Scott W. Lowe Antigen recognizing receptors targeting upar and uses thereof
WO2023183667A1 (en) * 2022-03-24 2023-09-28 The United States Government As Representative By The Department Of Veterans Affairs Urokinase-type plasminogen activator receptor binding peptides and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
DE10117381A1 (de) * 2001-04-06 2002-10-10 Wilex Biotechnology Gmbh Herstellung polyklonaler, monospezifischer Antikörper gegen die uPAR-Varianten del4, del5 und del4+5 sowie deren Verwendung für diagnostische und therapeutische Zwecke
WO2003079974A2 (en) * 2002-03-18 2003-10-02 The Arizona Board Of Regents On Behalf Of The University Of Arizona Integrin ligand
PT2117571T (pt) * 2006-12-08 2017-06-14 Monopar Therapeutics Inc Resumo

Also Published As

Publication number Publication date
JP4890449B2 (ja) 2012-03-07
PT1765397E (pt) 2013-02-04
CA2568428A1 (en) 2005-12-08
JP2008509086A (ja) 2008-03-27
AU2005248400A1 (en) 2005-12-08
RU2006145905A (ru) 2008-06-27
CA2568428C (en) 2020-12-29
CN101022830A (zh) 2007-08-22
US8101726B2 (en) 2012-01-24
WO2005116077A2 (en) 2005-12-08
DK1765397T3 (da) 2013-02-04
MXPA06013709A (es) 2008-01-16
WO2005116077A3 (en) 2005-12-29
EP1765397A4 (en) 2009-05-13
EP1765397A2 (en) 2007-03-28
US20090180952A1 (en) 2009-07-16
ES2398221T3 (es) 2013-03-14
KR20070047246A (ko) 2007-05-04
IL179565A0 (en) 2007-05-15
ZA200610578B (en) 2009-09-30
EP1765397B1 (en) 2012-10-24

Similar Documents

Publication Publication Date Title
PL1765397T3 (pl) Hamujące przeciwciała wiążące kompleks aktywatora plazminogenu typu urokinazy (uPA) i jego receptora (uPAR)
EP2117571A4 (en) UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR EPITOPE, DERIVED MONOCLONAL ANTIBODIES, AND METHODS OF USING THE SAME
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
HK1099935A1 (en) Anti-cd3 antibodies and methods of use thereof -cd3
EP1725586A4 (en) PARTIALLY CHARGED ANTIBODIES AND METHODS OF CONJUGATING SAID ANTIBODIES
EP1717250A4 (en) MONOCLONAL ANTIBODY AND ITS USE
IL197300A0 (en) Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
IL178593A (en) Specific antibodies of fcγriib and methods for their use
IL192129A0 (en) Anti-mn antibodies and methods of using same
LT2311873T (lt) Specifinis m-csf monokloninis antikūnas ir jo panaudojimas
HK1097607A1 (en) Polarizing devices and methods of making the same
EP1747522A4 (en) METHODS AND SYSTEMS FOR ENSURING GUARANTEED COMMERCIAL TRANSACTIONS
AP2004003192A0 (en) Combination of azelastine and steroids.
EP1833849A4 (en) FC-GAMMA-RIIB-SPECIFIC ANTIBODIES AND METHODS FOR THEIR USE
ZA200804960B (en) Promoter sequence obtained from rice and methods of use
EP1877079A4 (en) ELASTIN BINDING PROTEIN LIGANDS DERIVED FROM PLANTS AND METHODS OF USE
GB2421571B (en) Navigation apparatus and program of the same
GB0420062D0 (en) Assay methods,materials and preparations
EP1742654A4 (en) ANTI-LFL2 ANTIBODIES FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER
TWI318354B (en) Programmable transaction initiator architecture for systems with secure and non-secure modes
WO2006094828A3 (en) Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
TWI365777B (en) Ultrasonic transducer and method of operation the same
EP1793857A4 (en) COMBINED THERAPY WITH ANTI-CTLA4 AND ANTI-4-1BB ANTIBODIES
EP1718968A4 (en) CHROMATOGRAPHIC EXCLUSION AGGLUTINATION ASSAY AND METHODS OF USE
WO2006050177A8 (en) Antibodies that bind urokinase-type plasminogen activator and epitopes therefor